DSG3, His, Human

DSG3, His, Human

To identify genes that could potentially serve as molecular therapeutic markers for human head and neck cancer (HNC),DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. DSG3 is a potential molecular target in the development of adjuvant therapy for HNC.
Z05228
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
DSG3 (Glu50-Arg615)
Accession # P32926		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
> 90% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized DSG3, His, Human at 0.5μg/ml (100μl/Well) on the plate can bind Anti­DSG3 Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 64 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 70-75 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background To identify genes that could potentially serve as molecular therapeutic markers for human head and neck cancer (HNC),DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. DSG3 is a potential molecular target in the development of adjuvant therapy for HNC.
Synonyms Desmoglein-3; PVA; CDHF6; SG3; DSG3; DSG-3

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.